Search Results for "Linzess"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Linzess. Results 1 to 10 of 12 total matches.
See also: linaclotide
Linaclotide (Linzess) for Constipation
The Medical Letter on Drugs and Therapeutics • Nov 12, 2012 (Issue 1403)
Linaclotide (Linzess) for Constipation ...
Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest),
a guanylate cyclase-C receptor agonist, was recently
approved by the FDA for oral treatment of chronic idiopathic
constipation (CIC) and irritable bowel syndrome
with constipation (IBS-C) in adults. It is the second drug
approved for this indication; lubiprostone (Amitiza), a
metabolite of prostaglandin E1, was the first.
Linaclotide (Linzess) for Functional Constipation
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
Linaclotide (Linzess) for Functional Constipation ...
The guanylate cyclase-C receptor agonist linaclotide
(Linzess – Abbvie/Ironwood) was first approved by
the FDA in 2012 for treatment of chronic idiopathic
constipation and irritable bowel syndrome with
constipation in adults. The drug has now been
approved for treatment of functional constipation in
patients 6-17 years old. Linaclotide is the only drug
to be approved in the US for treatment of functional
constipation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):135-6 doi:10.58347/tml.2023.1683d | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
of lubiprostone Guanylate Cyclase-C Agonists
Linaclotide – Linzess
(Abbvie/Ironwood)
72, 145, 290 mcg caps ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721e | Show Introduction Hide Introduction
Plecanatide (Trulance) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Apr 24, 2017 (Issue 1519)
constipation (CIC)
in adults. Linaclotide (Linzess), another guanylate
cyclase-C receptor agonist ...
The FDA has approved plecanatide (Trulance –
Synergy), a guanylate cyclase-C receptor agonist,
for treatment of chronic idiopathic constipation (CIC)
in adults. Linaclotide (Linzess), another guanylate
cyclase-C receptor agonist, and lubiprostone (Amitiza),
a chloride channel activator, were approved earlier for
treatment of CIC in adults.
Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
cholestyramine colesevelam colestipol rifaximin ondansetron Zofran eluxadoline Viberzi alosetron Linzess ...
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1 doi:10.58347/tml.2025.1721c | Show Introduction Hide Introduction
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
or its effects on milk production
Linaclotide (Linzess) ▶ No adequate studies in pregnant women ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721b | Show Introduction Hide Introduction
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
with these remedies.2 Prescription options, which
include the prosecretory drugs linaclotide (Linzess),
plecanatide ...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 doi:10.58347/tml.2023.1675a | Show Introduction Hide Introduction
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
drug such as linaclotide (Linzess),
plecanatide (Trulance), or lubiprostone (Amitiza ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
, a secretagogue
such as lubiprostone (Amitiza, and generics),
linaclotide (Linzess), or plecanatide (Trulance ...
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor is the
first NHE3 inhibitor to become available in the US.
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
Linaclotide2 – Linzess
(Allergan/Ironwood)
72, 145, 290 mcg
caps
145 mcg PO once/day
≥30 mins before ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation